Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



A Solazyme Investor's Guide to 120,000 Tons of Renewable Oil

Last week we looked at the smallest and most important part of the industrial biotech industry: microbial production metrics. It is impossible to be profitable and successful without optimizing the microbes that power your platform. It is also critical to optimize the construction, commissioning, and ramp-up phases of a biorefinery to become profitable as quickly as possible. What is commissioning? How long does ramping up take? Why can't Solazyme investors expect 120,000 metric tons of oils to be produced by the end of 2014? Let's dissect these terms and lose the confusion. 

Industry round-up to ramp-up
The list of public industrial biotech companies is growing quickly, although some of the best companies remain in private hands. Here are some companies to keep your eye on that are either currently undergoing ramp-up or looking to do so soon at their first facilities:


Annual Capacity

Commissioning Date


Amyris (NASDAQ: AMRS  )

50 million liters



BioAmber (NYSE: BIOA  )

50,000 metric tons


Bio-succinic acid

Genomatica and Novamont

40 million pounds




18 million gallons



Solazyme (NASDAQ: TVIA  )

100,000 metric tons


Various oil profiles

Source: Company websites  

There will be dozens of announcements this year and next on progress from the commercial operations of these industrial biotechnology pioneers. While it is the responsibility of the companies to provide investors with a complete view of their bio-based chemical platforms, I fear that many investors may be isolated by unfamiliar terms. After all, these are the first companies hitting prime time. Getting lost during this important chapter of development for these disruptive companies could have disastrous results.

Shake, stir, wait 12-18 months (or longer)
Completing the construction of a biorefinery is not the end of the story. Commercial operation of facilities goes through three major phases:

  1. Commissioning
  2. Ramp-up
  3. Nameplate operation

During commissioning all equipment is tested and measured to ensure that it operates as designed. This usually consists of taking a biorefinery's upstream equipment (microbial seed trains, bioreactors, holding tanks, injection units, and the like) and downstream equipment (holding tanks, separation equipment, and the like) through several consecutive production runs. After successfully commissioning a facility, the doors are sprung open, engineers are stuffed into the control room, interns are banned (they just screw things up anyway), and the next phase begins.

Amyris' first commercial scale Biofene facility in Brazil may have come on line six months ago, but it will take nearly three years to reach full nameplate capacity of 50 million liters. Source: Amyris

Production at a biorefinery does not start from the often-quoted numbers, much to the chagrin -- or surprise -- of investors. In fact, it can take 12-36 months to reach the final production capacity, or nameplate capacity, of a facility. The time between start-up and nameplate operation is called ramp-up, which gradually raises the amount of product created. This gives engineers time to work out kinks that were not encountered during commissioning or conceived of previously while optimizing the facility's process scheduling -- the carefully orchestrated schedule of every piece of equipment in the facility.

Not all ramp-up is created equally, however, because companies choose to upgrade equipment on different schedules. For example, the jointly operated facility between Solazyme and Bunge in Brazil will take 12-18 months to reach 100,000 metric tons of capacity, while Amyris' first facility will gradually be ramped to 50 million liters of annual capacity over the course of 36 months. Similarly, Gevo is gradually bringing all of its production trains on line, so ramp-up will occur in multiple phases for the same facility.

That means that operating at less than nameplate capacity is a consequence of ramp-up. Despite having an annual nameplate capacity of 100,000 metric tons of renewable oils and beginning operations in the second half of 2013, Solazyme Bunge will not produce 100,000 metric tons of products between start-up and the second half of 2014.

Nameplate is the end, right?
Eventually, ramp-up reaches full nameplate capacity. Even this phase is not the end of the story, however. Engineers will continually improve the process to improve efficiency, lower manufacturing costs, and even increase annual production capacity. Of course, building biorefineries is only half of the commercialization equation. Products -- you know, the stuff actually generating cash -- must also be commercialized independently of equipment.

Foolish bottom line
There is a difference between bioreactor volumes and realized product volumes, but the interesting thing with synthetic biology is that we still don't know the ceiling. In 20 years from now, Solazyme's heterotrophic algae could be much more efficient at producing tailored oils and Amyris' will be producing more than one end product with the same strain of yeast. Their original facilities in Brazil, in Moema and Brotas, could eventually have their nameplate capacities raised on the heels of scientific advancements alone. No extra bioreactors required!

There are numerous intricacies involved in industrial biotechnology, but with the right information you won't get lost in some inevitably confusing press releases. I am a believer that the industry can really change the world -- and perhaps your retirement -- but it is important to remain patient and take a long-term approach. The Motley Fool's free report, "3 Stocks That Will Help You Retire Rich", not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.

Read/Post Comments (2) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 11, 2013, at 9:58 AM, Lachplesis wrote:

    I believe it would have been more beneficial for everyone if the comparisons used the same units of measurements.

    For example, at 0.813 g/mL, 50 millions liters of Farnesene equates to just 40,650 metric tons.

    Solazyme can sell their eventual 100,000 metric tons from their first plant for between $3K - $5K ton with costs around $1K/ton.

    How does farnesene copares to that? Solazyme will have additional capacities coming online starting next year (ADM). What plans for capacity growth do other companies in this sector have?

    Solazyme have sufficient cash reserves to see their current plans reach nameplate capacities. Are other companies in the same position?

  • Report this Comment On July 11, 2013, at 11:47 AM, TMFBlacknGold wrote:


    I could have put farnesene in metric tons, but the isobutanol and bio-succinic acid/BDO markets are usually described in gallons and pounds, respectively. These are building block molecules, after all. Not trying to trick anyone by any means.

    All companies have ambitious plans for growth in this sector. Amyris has a much larger facility half-built with SMA that will eventually come online, BioAmber has two more 50,000 metric ton (or larger) facilities coming online in the next three years, Genomatica has multiple plants with multiple products coming online in the next two years (plants as large as 100 million pounds per year), and Gevo claims it has "talked to various groups" representing several hundred million gallons of ethanol capacity (0.8x factor for isobutanol).

    I think it is obvious that Solazyme has done the best job raising funds thus far and is in a better financial position than Amyris, BioAmber, and Gevo. Genomatica has a much different business model than the group (purely licensing its massive IP portfolio) so its costs are nowhere near as high.

    I would also remind you that the 100,000 metric tons belong to the JV, not Solazyme, and that the equipment at its first facility will not be optimized to allow $1,000 per ton production costs (even at nameplate). The selling range per metric ton is also between $2,000 and $4,000 with a smaller amount of nutritional oils topping $5,000.


Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2531031, ~/Articles/ArticleHandler.aspx, 9/27/2016 6:39:50 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,228.30 133.47 0.74%
S&P 500 2,159.93 13.83 0.64%
NASD 5,305.71 48.22 0.92%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 4:00 PM
AMRS $0.49 Up +0.00 +0.06%
Amyris CAPS Rating: **
GEVO $0.48 Down -0.01 -1.31%
Gevo CAPS Rating: *
TVIA $2.79 Up +0.05 +1.82%
TerraVia CAPS Rating: ***